Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited has announced the release of 5,436,966 ordinary shares from voluntary escrow on 10 July 2024, as part of the company’s acquisition of ARTMS Inc. Telix, a Melbourne-based biopharmaceutical company, focuses on developing diagnostic and therapeutic radiopharmaceuticals for oncology and rare diseases. Its lead imaging product, Illuccix®, has gained approvals in the U.S., Australia, and Canada, signaling potential growth prospects for investors.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
